ABSTRACT
This study was aimed to establish an inspection method for the limited quantity of aconitine and the content determination of schisandrol in Yi-Shen Xiao-Zhong(YSXZ) pill.Thin layer chromatography (TLC) was used to inspect the limited quantity of aconitine in YSXZ pill.The content of schisandrol was determined by high-performance liquid chromatography (HPLC).The results showed that the identification method of the limited quantity of aconitine and the content determination method of schisandrol were established.Compared to the correspondent position of the control chromatography,the limited quantity of aconitine was 2.5μg,which was much lower than the dose of inducing toxic reaction.It can be used in the limited quantity control of aconitine for toxic reaction in YSXZ pill.The calibration curve of schisandrol was linear at 2.92-95.36μg·mL-1.The regression equation wasy = 18.630x + 2.556 (r = 1).The average recovery was 95.10% and RSD was 1.55% (n = 6).It was concluded that the established method for the inspection and content determination of aconitine and schisandrol was simple,accurate and reproducible.It can be used in the quality control of YSXZ pill.
ABSTRACT
Objective To investigate the relationship between CRP, plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 gene promoter 4G/5G polymorphism and the type of acute myocardial infarction (ST elevation myocardial infarction, STEMI vs the non-ST elevation Myocardial infarction, NSTEMI). Methods One hundred seventy-six consecutive patients with AMI were included for the study, of whom 60 had STEMI and 56 had NSTEMI, and 60 adults without cardiovascular and cerebrovascular disease were selected as controls. Blood samples were obtained from patients within 6 h of AMI and the plasma PAI-1, CRP, and the gene polymorphism were measured. Results Plasma levels of PAI-1 and CRP were higher in AMI groups, compared those in the control group, and plasma levels of PAI-1 were significantly higher in patients with STEMI compared to those with NSTEMI (80.12ng/ml VS.73.01ng/ml, P 0.05). PAI-1 levels presented a significant correlation with CRP levels in the NSTEMI subjects. However, PAI-1 and CRP levels could explain the lack of a significant relationship between them in control and STEMI subjects.The frequencies of 4G/4G genotype in the AMI group were higher than those in the control group and higher in patient with STEMI than in patient with NSTEMI. Plasma levels of PAI-1 in subjects with 4G/4G genotype were significantly increased as compared to those in subjects with 4G/5G and 5G/5G genotype. Conclusions Plasma PAI-1 levels were associated with different myocardial infarction type, and PAI-1 promoter 4G/5G polymorphisms and CRP may be related to plasma PAI-1 levels.